You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A CD8+ T cell diagnostic to identify children with pulmonary tuberculosis

    SBC: ViTi, Inc            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB disease which results from infection with Mycobacterium tuberculosis Mtb is a leading cause of infectious morbidity and mortality in children andlt years old worldwide In TB endemic regions in which the vast majority of the worldandapos s annual million adult cases of TB disease reside children andlt years old account for ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Position tracking and mobility assessment system for indoor monitoring of elders

    SBC: EMBEDRF LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The goal of this project is to develop and evaluate a position tracking and mobility assessment system that will enable the elderly to live longer and more safely at home or in an assisted living facility. The ability to move is a critical function tat underlies the quality of life for the elderly. Changes in mobility such as speed of walking have been shown to ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Monodispersed magnetic nanoparticles for improved diagnostic imaging. Phase II: S

    SBC: LODESPIN LABS, LLC            Topic: NIBIB

    DESCRIPTION (provided by applicant): In the proposed phase II NIH STTR funding opportunity (PA-12-089), LodeSpin Labs (LSL) is developing a magnetic nanoparticle tracer for use in Magnetic Particle Imaging (MPI), a disruptive new medical imaging technologycurrently being developed as a safe, effective and quantitative alternative to existing cardiac imaging technologies like CT and MRI. MPI is a p ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Autologous HIV-1 resistant T cells through accelerated CCR5 gene disruption

    SBC: PRECISION GENOME ENGINEERING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Treating patients infected with Human Immunodeficiency Virus-1 (HIV-1) is a substantial clinical challenge with evolving pharmaceutical drug and dosing options. Treatments should improve the health and quality of life for HIV-infected individuals by reducing viremia and preserving immunological function. Currents therapeutic approaches utilize combination antir ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Tau Protein Aggregation Inhibitors for Tauopathies

    SBC: PROTEOTECH, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid protein (A?), and neurofibrillary tangles (NFTs) containing aggregated tau protein. AD drug discovery efforts havebeen largely focused on reducing brain A? levels, with much less emphasis on tau-directed strategies. ProteoTech Inc. has developed a number ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Point-of-Care HIV Antigen/Antibody Diagnostic Device

    SBC: MBIO DIAGNOSTICS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based,4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflow of the widely used HIV rapid tests. Phase I research ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Phase II of VerOFy: A New Tool to Improve Productivity for Stress Research

    SBC: OASIS DIAGNOSTICS CORPORATION            Topic: NCCAM

    DESCRIPTION (provided by applicant): This Phase II SBIR builds upon the activities of R43-AT006634, VerOFy: A New Tool to Improve Productivity and Reduce Costs for Stress Research . Technology for an integrated sample collection system was developed whichnon-invasively measures salivary cortisol levels within minutes of sample collection; this is a substantial improvement over traditional immunoa ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Reducing Complement Inhibition to Treat Leukemia and Lymphoma

    SBC: PAI LIFE SCIENCES INC            Topic: NCI

    DESCRIPTION (provided by applicant): Funding of this application will move a new combination cancer therapy for leukemia and lymphomas towards human clinical trials. Monoclonal antibodies, mAbs have emerged as a rapidly growing class of oncology therapeutics. Despite their success in certain clinical applications, the therapeutic efficacy of mAbs is limited, with only a minority of patients resp ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government